The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis. This study will also to compare the efficacy of two oral doses of CP-690,550 (5 mg BID and 10 mg BID) after 16 weeks of treatment.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01519089?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
